FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and describes the agent for the treatment or prevention of an allergic condition. Agent, which is a liposome formulation comprising: (a) fragments of a Mycobacterium tuberculosis-complex (MTB-C) strain, (b) a liposome-forming agent, (b) 1 to 20 % sucrose. Also a liposomal agent is offered, where z-average particle size is equal to 150 nm or less, and a pharmaceutical composition comprising the specified agent.
EFFECT: group of inventions provides the prevention and treatment of asthma in a mammal, attenuates airway hyperresponsiveness, eosinophilia level and lymphocytosis in the airways of sensitized animals, due to content of 1-20 % weight/volume of sucrose and specific particle size (less than 150 nm) in liposomal agent.
32 cl, 15 dwg, 10 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LIPOSOME FORMULATION SUITABLE FOR TREATING OR PREVENTING TUBERCULOSIS | 2012 |
|
RU2648842C2 |
| PREVENTIVE ANTI-TUBERCULOSIS VACCINE | 2007 |
|
RU2526910C2 |
| IMMUNOTHERAPEUTIC AGENT FOR PRIMARY PREVENTION OF TUBERCULOSIS | 2009 |
|
RU2544125C2 |
| IMMUNOTERAPEUTIC AGENT SUITABLE FOR COMBINED TUBERCULOSIS TREATMENT COUPLED WITH OTHER MEDICAL PRODUCTS | 2004 |
|
RU2341287C2 |
| T CELL SPECTRUM BROADENING FOR SUB-DOMINANT EPITOPE INCLUSION BY VACCINATION WITH ANTIGENS DELIVERED AS PROTEIN FRAGMENTS OR PEPTIDE COCKTAILS | 2007 |
|
RU2490024C2 |
| FUSION PROTEIN, DNA, GENETIC CONSTRUCT, RECOMBINANT CELL, FUSION PROTEIN-BASED VACCINE FOR TUBERCULOSIS PREVENTION AND TREATMENT (VERSIONS) | 2015 |
|
RU2615440C2 |
| POLYANTIGENIC VACCINE FOR PREVENTING AND ADJUNCTIVE TREATMENT OF TUBERCULOSIS | 2019 |
|
RU2724896C1 |
| USE OF MONOMYCOLYL GLYCEROL (MMG) AS ADJUVANT | 2008 |
|
RU2479317C2 |
| VACCINES OF RECOMBINANT INTRACELLULAR PATHOGENS AND USES THEREOF | 2001 |
|
RU2266132C2 |
| MULTI-EPITOPE POLYPEPTIDE FOR IMMUNIZATION AGAINST MYCOBACTERIUM TUBERCULOSIS | 2023 |
|
RU2824195C1 |
